[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8,"_9":10},"actionData","errors","root",{"_105":106,"_107":59},"routes/en-gate",{"_104":59},"en-item-original",{"_11":12},"item",{"_13":14,"_15":16,"_17":18,"_19":18,"_20":-5,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":27,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":-5,"_40":42,"_43":-5,"_44":-5,"_45":-5,"_46":47,"_48":49,"_50":-5,"_51":52,"_53":54,"_55":56,"_57":38,"_58":59,"_60":-5,"_61":62,"_63":64,"_65":38,"_66":59,"_67":68},"id","eepxa5ym002nsuitnwkkbakpn","revision",2,"title","At #AACR26, Dr. Sam Cytryn","originalTitle","summary","reason","source",{"_13":98,"_79":99,"_100":101,"_102":38,"_103":-5},"links",{"_95":96,"_68":97},"publishedAt","2026-04-20T22:45:17.000Z","discoveredAt","2026-10-22T11:08:34.022Z","timelineAt","category","opinion","tags",[],"score",60,"selected",false,"channel","x","story",{"_88":89,"_90":49,"_91":-5,"_92":-5,"_93":94},"insight","digest","conferenceAbstracts","readingMode","full","author","jbuell01","language","body",{"_83":-5,"_68":84,"_85":86,"_87":59},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_77":78,"_79":80,"_81":-5,"_82":-5},"engagement",{"_69":70,"_71":72,"_73":74,"_75":76},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",15,"likes",11,"replies",0,"reposts",4,"slug","aacr-2026","name","AACR 2026 年会","topic","reading","zh","

At #AACR26, Dr. Sam Cytryn
@MSKCancerCenter
reports INKT+BOT/BAL and chemo in r/r GEJ:

- 20% survival beyond 3 years in r/r GEJ
- Immune activation across assays
- Activity in active liver mets

In refractory disease, durability defines impact.
@MiNK_iNKT

@Agenus_Bio

","zhKind","translation","complete","authorName","Jennifer Buell","handle","avatarUrl","quoted","media",[],"aihot","/items/eepxa5ym002nsuitnwkkbakpn","https://x.com/jbuell01/status/2046359579743883333","aacr26-floor","AACR 2026 现场信号","kind","x_search","firstParty","iconUrl","ok","changelogVersion","2026-10-23T01:25","enEditionEnabled"]